Avian influenza A(H5N1)
Avian influenza A(H5N1) is a flu virus that mainly infects birds, but it can sometimes infect people. The human cases reported to the World Health Organization have usually followed close contact with sick or dead birds, some infected mammals, or contaminated environments. WHO said that from 2003 to 2025 almost all reported human cases had this kind of exposure, and that sustained spread from person to person has not been documented in the recent notices retrieved here. Illness in people can range from mild infection or even no symptoms to severe pneumonia and death. In WHO’s global count, 986 human cases and 473 deaths were reported from 25 countries by 2025-07-01, which is a reported case fatality ratio of 48%, though this reflects detected cases and can change over time. Antiviral drugs such as oseltamivir and zanamivir may help, especially when started early. The sources retrieved here do not establish a widely used human vaccine for the general public, so vaccine status is listed as unknown.
Key facts
| Transmission | Usually zoonotic: close contact with infected live or dead birds, some infected mammals, or contaminated environments; human-to-human spread is not established as sustained in the retrieved WHO reports. |
|---|---|
| Incubation | unknown |
| Case fatality | 48% among 986 WHO-reported human cases worldwide from 2003 to 2025-07-01 (473 deaths); country figures vary, for example Cambodia reported 59% cumulatively since 2003 and 44% for cases reported after re-emergence in 2023-2025. |
| Reproduction number | unknown |
| Vaccine | unknown from the retrieved sources; no widely used public human vaccine was established in the documents reviewed here. |
| Treatment | Supportive care plus antivirals may help; WHO notes neuraminidase inhibitors such as oseltamivir and zanamivir have been shown to shorten viral replication and improve outcomes in some cases, and should be given within 48 hours of symptom onset. |
| Reservoir | Wild birds and poultry are the main reservoir; WHO also notes circulation in some mammals. |
| Endemic regions | Virus circulation in animals is global in wild birds, poultry, and some mammals; human infections reported to WHO came from 25 countries by 2025-07-01. |
Transmission
H5N1 is mainly an animal infection, not a routine human infection. In the WHO notices retrieved here, almost all human cases were linked to close contact with infected live or dead birds, infected mammals, or places contaminated by them. Cambodia’s 2025 report says all 11 cases that year had handled or culled sick poultry, often backyard birds. WHO’s assessments for recent cases in Cambodia, Mexico, Viet Nam, and the United States all say the same broad pattern: people were usually exposed to infected animals or contaminated environments, and no additional linked human cases were found during follow-up. That does not mean transmission between people is impossible, but the retrieved WHO reports say sustained human-to-human spread has not been documented. This matters because a shift toward easy person-to-person spread would greatly change the public-health risk.
- Avian Influenza A(H5N1) - Cambodia WHO · 5 Jul 2025
- Avian Influenza A(H5N1) - Mexico WHO · 17 Apr 2025
- Avian Influenza A(H5N1) – United States of America WHO · 9 Apr 2024
- Avian Influenza A(H5N1) – Viet Nam WHO · 2 Apr 2024
Symptoms and severity
Illness from H5N1 in people can look very different from one case to another. WHO’s Cambodia report says human infection may range from mild upper respiratory symptoms to severe, life-threatening disease. Reported features include conjunctivitis, breathing symptoms, stomach or bowel symptoms, encephalitis, and encephalopathy. Some infected people have had no symptoms at all and were found only because they were tested after exposure. Even so, the disease can be very serious. WHO reported 986 human cases and 473 deaths worldwide from 2003 to 2025-07-01, a reported case fatality ratio of 48%. Recent country reports also show that severity varies: Cambodia reported 49 deaths among 83 cumulative cases since 2003, while its re-emergence period from 2023 to 2025 had 12 deaths among 27 cases. These figures describe detected and reported cases, not necessarily every infection.
- Avian Influenza A(H5N1) - Cambodia WHO · 5 Jul 2025
- Avian Influenza A(H5N1)- Cambodia WHO · 2 Sept 2024
- Avian Influenza A(H5N1) – United States of America WHO · 9 Apr 2024
Treatment and vaccines
The clearest treatment information in the retrieved sources is about antivirals. WHO says neuraminidase inhibitors, especially oseltamivir and zanamivir, have been shown to shorten the time the virus replicates and may improve outcomes in some cases. WHO also says these medicines should be started within 48 hours of symptom onset. People with severe disease may also need hospital care and breathing support, but the retrieved WHO material does not give a full treatment protocol. On vaccines, the sources gathered in this session do not establish a broadly available human H5N1 vaccine for the general public, so vaccine status here is listed as unknown rather than guessed. That uncertainty should not be read as meaning vaccine research does not exist; it only means the documents retrieved for this page did not provide enough direct detail to state a clear public-facing vaccine recommendation.
- Avian Influenza A(H5N1) - Cambodia WHO · 5 Jul 2025
- Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Europe PMC · 1 Mar 2019
Where it occurs
H5N1 circulates widely in animals. WHO says the virus is present in wild birds, poultry, and some mammals around the world, so occasional human infections are expected where people have close exposure. By 2025-07-01, WHO had recorded 986 human cases from 25 countries. The recent WHO notices retrieved here show how scattered these events can be: Cambodia has reported repeated human cases; Viet Nam reported a fatal case in 2024; the United States reported a human infection linked to dairy cattle in 2024; Australia reported its first human H5N1 infection in 2024, likely acquired during travel; and Mexico reported its first confirmed human H5N1 infection in 2025. So this is not a disease confined to one country. The main pattern is global circulation in animals with uncommon, usually exposure-related human spillover.
- Avian Influenza A(H5N1) - Cambodia WHO · 5 Jul 2025
- Avian Influenza A(H5N1) - Mexico WHO · 17 Apr 2025
- Avian Influenza A (H5N1) - Australia WHO · 7 Jun 2024
- Avian Influenza A(H5N1) – United States of America WHO · 9 Apr 2024
Recent history
This site’s archive lists 71 past H5N1-related events, showing that the virus has appeared in public-health notices many times since the late 1990s. The recent pattern in the WHO material is still mostly sporadic human infection after animal exposure, but there are important changes in where those exposures are happening. Cambodia reported renewed human activity after several quiet years, with 6 cases in 2023, 10 in 2024, and 11 by 2025-07-01. In 2024, the United States reported a human case after exposure to infected dairy cattle, which WHO described as the first known human H5N1 infection acquired from contact with an infected mammal of that kind. Australia reported its first human H5N1 infection in 2024, and Mexico its first confirmed human H5N1 infection in 2025. WHO’s risk assessment in the retrieved notices remained low for the general population, while higher for people with occupational exposure.
- Avian Influenza A(H5N1) - Cambodia WHO · 5 Jul 2025
- Avian Influenza A(H5N1) - Mexico WHO · 17 Apr 2025
- Avian Influenza A (H5N1) - Australia WHO · 7 Jun 2024
- Avian Influenza A(H5N1) – United States of America WHO · 9 Apr 2024
What to watch
The biggest warning sign would be evidence that H5N1 is spreading efficiently from person to person, especially if contact tracing starts finding chains of infection without direct animal exposure. Another important signal would be spread into new animal hosts or new regions that increase human contact, as seen with dairy cattle in the United States and unusual mammal events such as cats in Poland. Public-health teams should also watch for antiviral resistance, because WHO’s current treatment advice relies on drugs like oseltamivir and zanamivir. Changes in disease severity would matter too: more severe illness, more deaths, or more infections in healthcare or household settings would all raise concern. Finally, if vaccines become available for high-risk groups, then supply and matching to circulating strains would matter. Right now, based on the WHO notices retrieved here, the general public risk remains low, but the situation needs continued monitoring because influenza viruses change over time.
- Avian Influenza A(H5N1) - Cambodia WHO · 5 Jul 2025
- Avian Influenza A(H5N1) – United States of America WHO · 9 Apr 2024
- Influenza A(H5N1) in cats – Poland WHO · 16 Jul 2023
- Avian Influenza A(H5N1) - Mexico WHO · 17 Apr 2025
Related outbreaks
- Avian influenza H5N1 Attention: high